The study by Ahfeldt et al. (74) identified at least two distinct molecular phenotypes in hMO derived from either PRKN−/−, or ATP13A2/DJ1 mutated lines, indicating that familial PD mutations induce different pathological cascades, which may call for different therapeutic strategies. This evidence concerns the gene PARK7 and Parkinson disease.